论文部分内容阅读
目的:观察他汀类调脂药物瑞舒伐他汀(Rosuvastatin)对2型糖尿病(type2diabetesmellitus,T2DM)大鼠早期动脉粥样硬化形成的影响,并探讨其可能的机制。方法:将45只雄性SD大鼠随机分为正常对照组(NC组)、2型糖尿病组(DM组)、2型糖尿病瑞舒伐他汀治疗组(DR组),每组15只。以喂高糖高脂饮食方法建立SD大鼠糖尿病模型,DM组、DR组给予高糖高脂饮食1个月后腹腔注射25mg/kg链脲佐菌素;NC组给予普通饮食,注射枸橼酸缓冲液作为对照。在此基础上,DR组给予瑞舒伐他汀5mg/(kg.d)灌胃,NC组、DM组给予生理盐水灌胃。16周后测定各组大鼠总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平与稳态血糖(BG)、稳态胰岛素(PGI)浓度,用免疫组化法检测主动脉血管壁白细胞分化抗原40(clusterofdifferentiation 40,CD40)及基质金属蛋白酶-2(MMP-2)、激活蛋白-1(activator protein-1,AP-1)的表达水平。结果:DM组、DR组TC、TG、LDL-C与BG水平较NC组均显著升高(F=33.71~426.05,q=5.26~40.82,P<0.01),但2组间各指标比较差异无显著性(P>0.05)。DR组CD40、MMP-2、AP-1表达水平和浸润的单核细胞数明显低于DM组(F=36.86~716.82,q=8.59~37.86,P<0.05),DR组主动脉内皮损伤明显轻于DM组。结论:瑞舒伐他汀能抑制CD40、MMP-2、AP-1表达和单核细胞浸润,防止早期AS形成。
Objective: To observe the effect of Rosuvastatin, a statin lipid-lowering drug, on the early atherosclerosis in type 2 diabetes mellitus (T2DM) rats and to explore its possible mechanism. Methods: Forty-five male Sprague-Dawley rats were randomly divided into normal control group (NC group), diabetes mellitus group (DM group), and type 2 diabetic rosuvastatin treatment group (DR group). Diabetic rats model was established by feeding high-sugar and high-fat diet. DM and DR groups were given intraperitoneal injection of streptozotocin (25mg / kg streptozotocin) 1 month later. The rats in NC group were given normal diet and citron Acid buffer served as a control. On this basis, DR group was given rosuvastatin 5mg / (kg.d) gavage, NC group, DM group given saline. After 16 weeks, the levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and steady-state blood glucose (BG) and homeostasis insulin (PGI) Histochemistry was used to detect the expression of cluster of differentiation 40 (40) and the expression of matrix metalloproteinase-2 (MMP-2) and activator protein-1 (AP-1) Results: The levels of TC, TG, LDL-C and BG in DM group and DR group were significantly higher than those in NC group (F = 33.71-426.05, q = 5.26-40.82, P <0.01) No significant (P> 0.05). The expression of CD40, MMP-2, AP-1 and infiltration of monocytes in DR group were significantly lower than those in DM group (F = 36.86-716.82, q = 8.59-37.86, P <0.05) Lighter than DM group. Conclusion: Rosuvastatin can inhibit the expression of CD40, MMP-2, AP-1 and monocyte infiltration and prevent the formation of early AS.